Daratumumab Combination Therapy
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
What will happen during the trial?
This phase II, multicenter, open-label study is studying daratumumab in combination with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma who have received at least one prior therapy and who have had previous treatment with both lenalidomide and a proteasome inhibitor.
- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. This research study involves two study drugs and two standard of care drugs.
- The names of the study drugs involved in this study are:
- Carfilzomib
- Daratumumab
- The names of the standard of care drugs involved in this study are:
- Dexamethasone
- Pomalidomide
- A total of 43 participants will be enrolled to this trial
- The U.S. Food and Drug Administration (FDA) has not approved Daratumumab, and Carfilzomib for use in treatment of Multiple Myeloma.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 43 patients (estimated)
- Sponsors
- Massachusetts General Hospital
- Collaborators
- Amgen, Janssen Research & Development LLC
- Tags
- Monoclonal Antibody, Proteasome Inhibitor, CD38
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1068
- NCT Identifier
- NCT04176718
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.